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TO THE EDITORThe Bioresorbable
Scaffold
Will Oversizing Affect Outcomes?Stent strut thickness is associated with both an-
giographic restenosis (1) and thrombogenicity (2).FIGURE 1 Comparison of Absorb BRS and Metallic DES Strut Charact
(A) Hoops and links in the current Absorb bioresorbable scaffold (BRS). M
the links, and red arrows, the hoops of Absorb BRS (Abbott Vascular). (B)
(Cordis Corporation, Johnson & Johnson), and Xience V (Abbott Vascula
(link and hoop part), and percentages of abluminal strut surface area (A
pictures have been reproduced with permission from Elsevier and WolteIn addition, narrow struts may promote early neo-
intimal coverage (3). On the other hand, thick and
wide struts give a device higher radial strength and
plaque coverage. Therefore, stent design has long
been a compromise between strut thickness and
radial strength. Given the increased strut thickness
and width of the current bioresorbable scaffolds
(BRS), concerns exist regarding appropriate scaffold
sizing, which will affect scaffold/artery ratio.
The strut thickness of the Absorb BRS (Abbott
Vascular, Santa Clara, California) is 157 mm, whicheristics
acroscopic picture showing the scaffold structure.White arrows show
Strut thickness and width of 3.0-mm Absorb BRS, Cypher Bx Velocity
r) metallic stents. The table summarizes the strut thickness, width
SSA) when implanted to the nominal size of the vessel. Macroscopic
rs Kluwer (4,5).
FIGURE 2 Strut Surface Area and Volume of 3.0-mm Absorb BRS, Cypher Bx Velocity, and Xience V Metallic Stents
Percentages of (A) abluminal strut surface area (ASSA) and (B) strut volume when a 3.0-mm device is implanted and dilated against different-
sized vessels are shown. Absorb BRS (Abbott Vascular), Cypher Bx Velocity (Cordis Corporation, Johnson & Johnson), and Xience V (Abbott
Vascular).
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300is roughly equivalent to the ﬁrst-generation drug-
eluting Cypher stent (Cypher Bx Velocity 152.6 mm,
Cordis Corporation, Johnson & Johnson, Warren, New
Jersey), and almost double the second-generation
Xience stent (Xience V 81.3 mm, Abbott Vascular).
However, the strut width is signiﬁcantly larger in the
Absorb BRS (2.5- and 3.0-mm: 190.5 mm, and 3.5-mm:
215.9 mm) in comparison to the metallic stents (Cypher
130 mm, and Xience V 81.3 mm) (Figure 1).
As shown Figure 2, if a 3.0-mm Absorb BRS is
implanted in a 3.0-mm vessel, the scaffold occupies
27% of the vessel surface area and 5.7% of the vessel
volume. However, if the same scaffold is implanted
into a smaller vessel (2.5 mm), these percentages
increase to 32.4% (vessel surface area) and 8.1% (vessel
volume) (Figure 2). This fact may increase thrombo-
genicity and neointimal thickness, and impede the
early neointimal coverage of the struts. By contrast,
the larger size of BRS may have increased radial
strength and lesion coverage when compared with
smaller BRS and therefore may prevent restenosis and
plaque prolapse. Considering these issues, proper
sizing of BRS by intravascular imaging modalities
including intravascular ultrasound or optical coher-
ence tomography (or quantitative coronary angiog-
raphy) is strongly recommended in order to limit
excessive scaffold/artery ratio.Hiroyoshi Kawamoto, MD
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